CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,629 enrolled
Drug / intervention
Neriviodevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05443659
NCT05443659N/ACompleted
CompareCT.gov

Real-World Analysis of Remote Electrical Neuromodulation (REN) for the Acute Treatment of Migraine in Adolescence

Theranica·observational·Posted Jul 5, 2022·Updated Nov 4, 2025

In Brief

An observational study evaluating Nerivio for Migraine in Adolescence. Completed, enrolled 1,629 participants across 2 sites in 2 countries.

Detailed Summary

This is a Post-marketing study investigating the safety and efficacy of the REN device (Nerivio by Theranica, Israel) in adolescents with migraine. Data analysis concerning the REN treatment efficacy in terms of pain and functional disability as a standalone treatment or in combination with other medications will be performed.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine in Adolescence
CountriesIsrael, United States
Collaborators--

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedJul 5, 2022
Enrollment StartJan 1, 2021
Primary CompletionMay 31, 2022
Study CompletionAug 24, 2022
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 4.0 years ago

Interventions

Neriviodevice

Remote electrical neuromodulation (REN) device for the acute treatment of migraines. The device delivers transcutaneous electrical stimulation to the upper arm to induce conditioned pain modulation(CPM) that activates a descending endogenous analgesic mechanism. The treatment is self-administered and controlled by a smartphone application.